Early Results of Prostate Cancer Drug Clinical Trial Appear Encouraging, Nymox Says

Early Results of Prostate Cancer Drug Clinical Trial Appear Encouraging, Nymox Says
Nymox Pharmaceutical Corp. recently announced the 18-month results from its 40-month Phase 2 clinical trial (NX03-0040) of fexapotide triflutate (NX-1207) in localized prostate cancer. The results revealed the study endpoints were met and that cancer progression was improved in the groups of patients who were treated with fexapotide. NX-1207 is a novel drug that can be administered by a

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *